1
|
Akiyoshi K, Fujimori T, Fu X, Shah AP, Yamaguchi A, Steenbergen C, Santhanam L, Berkowitz D, Tuday E, Baraban JM, Das S. Adenosine A 2A Receptor Regulates microRNA-181b Expression in Aorta: Therapeutic Implications for Large-Artery Stiffness. J Am Heart Assoc 2023:e028421. [PMID: 37421280 PMCID: PMC10382090 DOI: 10.1161/jaha.122.028421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/06/2022] [Accepted: 05/05/2023] [Indexed: 07/10/2023]
Abstract
Background The identification of large-artery stiffness as a major, independent risk factor for cardiovascular disease-associated morbidity and death has focused attention on identifying therapeutic strategies to combat this disorder. Genetic manipulations that delete or inactivate the translin/trax microRNA-degrading enzyme confer protection against aortic stiffness induced by chronic ingestion of high-salt water (4%NaCl in drinking water for 3 weeks) or associated with aging. Therefore, there is heightened interest in identifying interventions capable of inhibiting translin/trax RNase activity, as these may have therapeutic efficacy in large-artery stiffness. Methods and Results Activation of neuronal adenosine A2A receptors (A2ARs) triggers dissociation of trax from its C-terminus. As A2ARs are expressed by vascular smooth muscle cells (VSMCs), we investigated whether stimulation of A2AR on vascular smooth muscle cells promotes the association of translin with trax and, thereby increases translin/trax complex activity. We found that treatment of A7r5 cells with the A2AR agonist CGS21680 leads to increased association of trax with translin. Furthermore, this treatment decreases levels of pre-microRNA-181b, a target of translin/trax, and those of its downstream product, mature microRNA-181b. To check whether A2AR activation might contribute to high-salt water-induced aortic stiffening, we assessed the impact of daily treatment with the selective A2AR antagonist SCH58261 in this paradigm. We found that this treatment blocked aortic stiffening induced by high-salt water. Further, we confirmed that the age-associated decline in aortic pre-microRNA-181b/microRNA-181b levels observed in mice also occurs in humans. Conclusions These findings suggest that further studies are warranted to evaluate whether blockade of A2ARs may have therapeutic potential in treating large-artery stiffness.
Collapse
Affiliation(s)
- Kei Akiyoshi
- Department of Anesthesiology and Critical Care Medicine Johns Hopkins School of Medicine Baltimore MD USA
| | - Tomonari Fujimori
- Department of Anesthesiology and Critical Care Medicine Johns Hopkins School of Medicine Baltimore MD USA
| | - Xiuping Fu
- Department of Intelligent Medical Engineering, School of Life Science Tiangong University Tianjin China
| | - Aparna P Shah
- Solomon H. Snyder Department of Neuroscience Johns Hopkins School of Medicine Baltimore MD USA
| | - Atsushi Yamaguchi
- Department of Cardiovascular Surgery, Saitama Medical Center Jichi Medical University Saitama Japan
| | | | - Lakshmi Santhanam
- Department of Anesthesiology and Critical Care Medicine Johns Hopkins School of Medicine Baltimore MD USA
| | - Dan Berkowitz
- Department of Anesthesiology and Perioperative Medicine The University of Alabama at Birmingham Birmingham AL USA
| | - Eric Tuday
- Division of Cardiovascular Medicine, Department of Internal Medicine, School of Medicine University of Utah Salt Lake City UT USA
- Geriatric Research, Education and Clinical Center VA Salt Lake City Health Care System Salt Lake City UT USA
| | - Jay M Baraban
- Department of Intelligent Medical Engineering, School of Life Science Tiangong University Tianjin China
- Department of Psychiatry and Behavioral Sciences Johns Hopkins School of Medicine Baltimore MD USA
| | - Samarjit Das
- Department of Anesthesiology and Critical Care Medicine Johns Hopkins School of Medicine Baltimore MD USA
- Department of Pathology Johns Hopkins School of Medicine Baltimore MD USA
| |
Collapse
|
2
|
Purinoceptor: a novel target for hypertension. Purinergic Signal 2023; 19:185-197. [PMID: 35181831 PMCID: PMC9984596 DOI: 10.1007/s11302-022-09852-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2021] [Accepted: 02/08/2022] [Indexed: 12/11/2022] Open
Abstract
Hypertension is the leading cause of morbidity and mortality globally among all cardiovascular diseases. Purinergic signalling plays a crucial role in hypertension through the sympathetic nerve system, neurons in the brain stem, carotid body, endothelium, immune system, renin-angiotensin system, sodium excretion, epithelial sodium channel activity (ENaC), and renal autoregulation. Under hypertension, adenosine triphosphate (ATP) is released as a cotransmitter from the sympathetic nerve. It mediates vascular tone mainly through P2X1R activation on smooth muscle cells and activation of P2X4R and P2YR on endothelial cells and also via interaction with other purinoceptors, showing dual effects. P2Y1R is linked to neurogenic hypertension. P2X7R and P2Y11R are potential targets for immune-related hypertension. P2X3R located on the carotid body is the most promising novel therapeutic target for hypertension. A1R, A2AR, A2BR, and P2X7R are all related to renal autoregulation, which contribute to both renal damage and hypertension. The main focus is on the evidence addressing the involvement of purinoceptors in hypertension and therapeutic interventions.
Collapse
|
3
|
Hoff U, Bubalo G, Fechner M, Blum M, Zhu Y, Pohlmann A, Hentschel J, Arakelyan K, Seeliger E, Flemming B, Gürgen D, Rothe M, Niendorf T, Manthati VL, Falck JR, Haase M, Schunck W, Dragun D. A synthetic epoxyeicosatrienoic acid analogue prevents the initiation of ischemic acute kidney injury. Acta Physiol (Oxf) 2019; 227:e13297. [PMID: 31077555 DOI: 10.1111/apha.13297] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2018] [Revised: 05/08/2019] [Accepted: 05/08/2019] [Indexed: 12/19/2022]
Abstract
AIM Imbalances in cytochrome P450 (CYP)-dependent eicosanoid formation may play a central role in ischemic acute kidney injury (AKI). We reported previously that inhibition of 20-hydroxyeicosatetraenoic acid (20-HETE) action ameliorated ischemia/reperfusion (I/R)-induced AKI in rats. Now we tested the hypothesis that enhancement of epoxyeicosatrienoic acid (EET) actions may counteract the detrimental effects of 20-HETE and prevent the initiation of AKI. METHODS Male Lewis rats underwent right nephrectomy and ischemia was induced by 45 min clamping of the left renal pedicle followed by up to 48 h of reperfusion. Circulating CYP-eicosanoid profiles were compared in patients who underwent cardiac surgery with (n = 21) and without (n = 38) developing postoperative AKI. RESULTS Ischemia induced an about eightfold increase of renal 20-HETE levels, whereas free EETs were not accumulated. To compensate for this imbalance, a synthetic 14,15-EET analogue was administered by intrarenal infusion before ischemia. The EET analogue improved renal reoxygenation as monitored by in vivo parametric MRI during the initial 2 h reperfusion phase. The EET analogue improved PI3K- as well as mTORC2-dependent rephosphorylation of Akt, induced inactivation of GSK-3β, reduced the development of tubular apoptosis and attenuated inflammatory cell infiltration. The EET analogue also significantly alleviated the I/R-induced drop in creatinine clearance. Patients developing postoperative AKI featured increased preoperative 20-HETE and 8,9-EET levels. CONCLUSIONS Pharmacological interventions targeting the CYP-eicosanoid pathway could offer promising new options for AKI prevention. Individual differences in CYP-eicosanoid formation may contribute to the risk of developing AKI in clinical settings.
Collapse
Affiliation(s)
- Uwe Hoff
- Nephrology and Intensive Care Medicine, Center for Cardiovascular Research Charité‐Universitätsmedizin Berlin Berlin Germany
| | - Gordana Bubalo
- Nephrology and Intensive Care Medicine, Center for Cardiovascular Research Charité‐Universitätsmedizin Berlin Berlin Germany
| | - Mandy Fechner
- Nephrology and Intensive Care Medicine, Center for Cardiovascular Research Charité‐Universitätsmedizin Berlin Berlin Germany
| | | | - Ye Zhu
- Nephrology and Intensive Care Medicine, Center for Cardiovascular Research Charité‐Universitätsmedizin Berlin Berlin Germany
- Department of Nephrology The Fifth Affiliated Hospital of Sun Yat‐sun University Zhuhai China
| | - Andreas Pohlmann
- Berlin Ultrahigh Field Facility (B.U.F.F.) Max Delbrueck Center for Molecular Medicine Berlin Germany
| | - Jan Hentschel
- Berlin Ultrahigh Field Facility (B.U.F.F.) Max Delbrueck Center for Molecular Medicine Berlin Germany
| | - Karen Arakelyan
- Berlin Ultrahigh Field Facility (B.U.F.F.) Max Delbrueck Center for Molecular Medicine Berlin Germany
- Center for Cardiovascular Research, Institute of Physiology Charité‐Universitätsmedizin Berlin Berlin Germany
| | - Erdmann Seeliger
- Center for Cardiovascular Research, Institute of Physiology Charité‐Universitätsmedizin Berlin Berlin Germany
| | - Bert Flemming
- Center for Cardiovascular Research, Institute of Physiology Charité‐Universitätsmedizin Berlin Berlin Germany
| | - Dennis Gürgen
- Nephrology and Intensive Care Medicine, Center for Cardiovascular Research Charité‐Universitätsmedizin Berlin Berlin Germany
| | | | - Thoralf Niendorf
- Max Delbrueck Center for Molecular Medicine Berlin Germany
- Berlin Ultrahigh Field Facility (B.U.F.F.) Max Delbrueck Center for Molecular Medicine Berlin Germany
| | | | - John R. Falck
- Biochemistry Department UT Southwestern Dallas Texas
| | - Michael Haase
- Medical Faculty Otto‐von‐Guericke University Magdeburg Germany
- Diaverum Deutschland Potsdam Germany
| | | | - Duska Dragun
- Nephrology and Intensive Care Medicine, Center for Cardiovascular Research Charité‐Universitätsmedizin Berlin Berlin Germany
| |
Collapse
|
4
|
Esselink AC, Bril LM, Langenhuijsen RW, Bilos A, Riksen NP, Rongen GA. Effect of two dosages of sodium chloride intake on the blood pressure response to caffeinated coffee in humans in vivo. Int J Food Sci Nutr 2019; 70:1014-1019. [DOI: 10.1080/09637486.2019.1595541] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Affiliation(s)
- Anne C. Esselink
- Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
- Department of Pharmacology-Toxicology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Lisanne M. Bril
- Department of Pharmacology-Toxicology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Renée W. Langenhuijsen
- Department of Gastro-Enterology and Hepatology, Dietetics and Intestinal Failure, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Albert Bilos
- Department of Pharmacology-Toxicology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Niels P. Riksen
- Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Gerard A. Rongen
- Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
- Department of Pharmacology-Toxicology, Radboud University Medical Center, Nijmegen, The Netherlands
| |
Collapse
|
5
|
Reduced coronary reactive hyperemia in mice was reversed by the soluble epoxide hydrolase inhibitor (t-AUCB): Role of adenosine A 2A receptor and plasma oxylipins. Prostaglandins Other Lipid Mediat 2017; 131:83-95. [PMID: 28890385 DOI: 10.1016/j.prostaglandins.2017.09.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2017] [Revised: 08/28/2017] [Accepted: 09/05/2017] [Indexed: 12/24/2022]
Abstract
Coronary reactive hyperemia (CRH) protects the heart against ischemia. Adenosine A2AAR-deficient (A2AAR-/-) mice have increased expression of soluble epoxide hydrolase (sEH); the enzyme responsible for breaking down the cardioprotective epoxyeicosatrienoic acids (EETs) to dihydroxyeicosatrienoic acids (DHETs). sEH-inhibition enhances CRH, increases EETs, and modulates oxylipin profiles. We investigated the changes of oxylipins and their impact on CRH in A2AAR-/- and wild type (WT) mice. We hypothesized that the attenuated CRH in A2AAR-/- mice is mediated by changes in oxylipin profiles, and that it can be reversed by either sEH- or ω-hydroxylases-inhibition. Compared to WT mice, A2AAR-/- mice had attenuated CRH and changed oxylipin profiles, which were consistent between plasma and heart perfusate samples, including decreased EET/DHET ratios, and increased hydroxyeicosatetraenoic acids (HETEs). Plasma oxylipns in A2AAR-/- mice indicated an increased proinflammatory state including increased ω-terminal HETEs, decreased epoxyoctadecaenoic/dihydroxyoctadecaenoic acids (EpOMEs/DiHOMEs) ratios, increased 9-hydroxyoctadecadienoic acid, and increased prostanoids. Inhibition of either sEH or ω-hydroxylases reversed the reduced CRH in A2AAR-/- mice. In WT and sEH-/- mice, blocking A2AAR decreased CRH. These data demonstrate that A2AAR-deletion was associated with changes in oxylipin profiles, which may contribute to the attenuated CRH. Also, inhibition of sEH and ω-hydroxylases reversed the reduction in CRH.
Collapse
|
6
|
Fleming I. The factor in EDHF: Cytochrome P450 derived lipid mediators and vascular signaling. Vascul Pharmacol 2016; 86:31-40. [DOI: 10.1016/j.vph.2016.03.001] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2015] [Revised: 01/20/2016] [Accepted: 03/06/2016] [Indexed: 12/31/2022]
|
7
|
EETs and HO-1 cross-talk. Prostaglandins Other Lipid Mediat 2016; 125:65-79. [DOI: 10.1016/j.prostaglandins.2016.06.002] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2016] [Revised: 06/03/2016] [Accepted: 06/20/2016] [Indexed: 01/26/2023]
|
8
|
Falck JR, Koduru SR, Mohapatra S, Manne R, Atcha KR, Atcha R, Manthati VL, Capdevila JH, Christian S, Imig JD, Campbell WB. 14,15-Epoxyeicosa-5,8,11-trienoic Acid (14,15-EET) surrogates: carboxylate modifications. J Med Chem 2014; 57:6965-72. [PMID: 25119815 PMCID: PMC4148164 DOI: 10.1021/jm500262m] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
![]()
The cytochrome P450 eicosanoid 14,15-epoxyeicosa-5,8,11-trienoic
acid (14,15-EET) is a powerful endogenous autacoid that has been ascribed
an impressive array of physiologic functions including regulation
of blood pressure. Because 14,15-EET is chemically and metabolically
labile, structurally related surrogates containing epoxide bioisosteres
were introduced and have become useful in vitro pharmacologic tools
but are not suitable for in vivo applications. A new generation of
EET mimics incorporating modifications to the carboxylate were prepared
and evaluated for vasorelaxation and inhibition of soluble epoxide
hydrolase (sEH). Tetrazole 19 (ED50 0.18 μM)
and oxadiazole-5-thione 25 (ED50 0.36 μM)
were 12- and 6-fold more potent, respectively, than 14,15-EET as vasorelaxants;
on the other hand, their ability to block sEH differed substantially,
i.e., 11 vs >500 nM. These data will expedite the development of
potent
and specific in vivo drug candidates.
Collapse
Affiliation(s)
- John R Falck
- Departments of Biochemistry and Pharmacology, University of Texas Southwestern Medical Center , 5323 Harry Hines Boulevard, Dallas, Texas 75390, United States
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Hye Khan MA, Neckár J, Manthati V, Errabelli R, Pavlov TS, Staruschenko A, Falck JR, Imig JD. Orally active epoxyeicosatrienoic acid analog attenuates kidney injury in hypertensive Dahl salt-sensitive rat. Hypertension 2013; 62:905-13. [PMID: 23980070 PMCID: PMC3872985 DOI: 10.1161/hypertensionaha.113.01949] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2013] [Accepted: 08/02/2013] [Indexed: 12/20/2022]
Abstract
Salt-sensitive hypertension leads to kidney injury. The Dahl salt-sensitive hypertensive rat (Dahl SS) is a model of salt-sensitive hypertension and progressive kidney injury. The current set of experimental studies evaluated the kidney protective potential of a novel epoxyeicosatrienoic acid analog (EET-B) in Dahl SS hypertension. Dahl SS rats receiving high-salt diet were treated with EET-B (10 mg/kg per day) or vehicle in drinking water for 14 days. Urine, plasma, and tissue samples were collected at the end of the treatment protocol to assess kidney injury, oxidative stress, inflammation, and endoplasmic reticulum stress. EET-B treatment in Dahl SS rats markedly reduced urinary albumin and nephrin excretion by 60% to 75% along with 30% to 60% reductions in glomerular injury, intratubular cast formation, and kidney fibrosis without affecting blood pressure. In Dahl SS rats, EET-B treatment further caused marked reduction in oxidative stress with 25% to 30% decrease in kidney malondialdehyde content along with 42% increase of nitrate/nitrite and a 40% reduction of 8-isoprostane. EET-B treatment reduced urinary monocyte chemoattractant protein-1 by 50% along with a 40% reduction in macrophage infiltration in the kidney. Treatment with EET-B markedly reduced renal endoplasmic reticulum stress in Dahl SS rats with reduction in the kidney mRNA expressions and immunoreactivity of glucose regulatory protein 78 and C/EBP homologous protein. In summary, these experimental findings reveal that EET-B provides kidney protection in Dahl SS rats by reducing oxidative stress, inflammation, and endoplasmic reticulum stress, and this protection was independent of reducing blood pressure.
Collapse
Affiliation(s)
- Md Abdul Hye Khan
- Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226.
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Capdevila J, Wang W. Role of cytochrome P450 epoxygenase in regulating renal membrane transport and hypertension. Curr Opin Nephrol Hypertens 2013; 22:163-9. [PMID: 23302865 DOI: 10.1097/mnh.0b013e32835d911e] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
PURPOSE OF REVIEW Cytochrome P450 (CYP)-epoxygenase is highly expressed in the kidney and its metabolism of arachidonic acid plays important roles in regulating renal Na transport and in modulating vasoactivity in the kidney. In the past several years, progress has been made not only in characterizing the specific CYP-epoxygenases responsible for the regulation of membrane transport and vasoactivity in the kidney but also in exploring the mechanism by which they regulate renal Na transport and vasodilation of preglomerular arterioles. This review summarizes and updates recent progress in this area of research. RECENT FINDINGS CYP-epoxygenase metabolites of arachidonic acid inhibit epithelial Na channel (ENaC) in the cortical collecting duct (CCD), and 11,12-epoxyeicosatrienoic acid (11,12-EET) is mainly responsible for mediating the inhibitory effect on ENaC. Downregulation of CYP2C44 abolishes arachidonic acid mediated inhibition of ENaC and increases ENaC activity. In addition, 11,12-EET stimulates Ca-activated big conductance K channels in the CCD and afferent arterioles smooth muscles. Activation of big conductance K channels by 11,12-EET is responsible for EET-induced vasodilation in preglomerular arterioles. 11,12-EET-induced vasodilation is absent in preglomerular arterioles pretreated with okadaic acid. SUMMARY CYP-epoxygenase mediated suppression of renal Na transport is partially achieved by inhibition of ENaC activity in the CCD and CYP2C44-derived EETs are responsible for inhibition of ENaC. Stimulation of serine/threonine protein phosphatase 2A (PP2A) contributes to 11,12-EET-induced activation of big conductance K channels and vasodilation in preglomerular arterioles.
Collapse
Affiliation(s)
- Jorge Capdevila
- Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA
| | | |
Collapse
|
11
|
Kusch A, Hoff U, Bubalo G, Zhu Y, Fechner M, Schmidt-Ullrich R, Marko L, Müller DN, Schmidt-Ott KM, Gürgen D, Blum M, Schunck WH, Dragun D. Novel signalling mechanisms and targets in renal ischaemia and reperfusion injury. Acta Physiol (Oxf) 2013; 208:25-40. [PMID: 23432924 DOI: 10.1111/apha.12089] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2012] [Revised: 11/26/2012] [Accepted: 02/14/2013] [Indexed: 12/16/2022]
Abstract
Acute kidney injury (AKI) induced by ischaemia and reperfusion (I/R) injury is a common and severe clinical problem. Vascular dysfunction, immune system activation and tubular epithelial cell injury contribute to functional and structural deterioration. The search for novel therapeutic interventions for I/R-induced AKI is a dynamic area of experimental research. Pharmacological targeting of injury mediators and corresponding intracellular signalling in endothelial cells, inflammatory cells and the injured tubular epithelium could provide new opportunities yet may also pose great translational challenge. Here, we focus on signalling mediators, their receptors and intracellular signalling pathways which bear potential to abrogate cellular processes involved in the pathogenesis of I/R-induced AKI. Sphingosine 1 phosphate (S1P) and its respective receptors, cytochrome P450 (CYP450)-dependent vasoactive eicosanoids, NF-κB- and protein kinase-C (PKC)-related pathways are representatives of such 'druggable' pleiotropic targets. For example, pharmacological agents targeting S1P and PKC isoforms are already in clinical use for treatment for autoimmune diseases and were previously subject of clinical trials in kidney transplantation where I/R-induced AKI occurs as a common complication. We summarize recent in vitro and in vivo experimental studies using pharmacological and genomic targeting and highlight some of the challenges to clinical application of these advances.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - M. Blum
- Max-Delbrück Center for Molecular Medicine; Berlin; Germany
| | - W.-H. Schunck
- Max-Delbrück Center for Molecular Medicine; Berlin; Germany
| | | |
Collapse
|